Neuroglee Therapeutics, a Singapore-based health tech startup building evidence-based, prescription digital therapeutics for neurodegenerative diseases, announced today that it has raised US$2.3 million in pre-seed funding.
The round was led by Eisai, a Japanese global pharmaceutical company. Kuldeep Singh Rajput, Founder & CEO of Biofourmis, also participated in the investment round.
As per a press note, proceeds will be used to advance product development for their lead product NG-001 – intended for the treatment and management of patients with early stages of Alzheimer’s Disease. Clinical trials are due to start in early 2021 and the startup plans to open its US operations in Boston in 2021.
Neuroglee designs and commercializes digital therapies to fill the unmet need for complementary therapies to manage neurodegenerative diseases that can run in parallel with pharmacotherapy or treatment through medication.
Combining closed-loop cognitive intervention strategies and novel biomarkers, Neuroglee claims its prescription software can be used independently and in conjunction with pharmacotherapy for better patient management, creating a more holistic approach to treatment for neurodegenerative diseases.